AU2003203553A1 - Cancer diagnostic panel - Google Patents
Cancer diagnostic panel Download PDFInfo
- Publication number
- AU2003203553A1 AU2003203553A1 AU2003203553A AU2003203553A AU2003203553A1 AU 2003203553 A1 AU2003203553 A1 AU 2003203553A1 AU 2003203553 A AU2003203553 A AU 2003203553A AU 2003203553 A AU2003203553 A AU 2003203553A AU 2003203553 A1 AU2003203553 A1 AU 2003203553A1
- Authority
- AU
- Australia
- Prior art keywords
- dna
- human
- seq
- genes
- microarray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 16
- 201000011510 cancer Diseases 0.000 title claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 108
- 241000282414 Homo sapiens Species 0.000 claims description 102
- 230000014509 gene expression Effects 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 49
- 238000002493 microarray Methods 0.000 claims description 28
- 239000011159 matrix material Substances 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims 2
- 238000010208 microarray analysis Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 description 24
- 238000005259 measurement Methods 0.000 description 20
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 238000004393 prognosis Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 238000012340 reverse transcriptase PCR Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000000683 nonmetastatic effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101150106899 28 gene Proteins 0.000 description 2
- 101150094765 70 gene Proteins 0.000 description 2
- 102100026663 All-trans-retinol dehydrogenase [NAD(+)] ADH7 Human genes 0.000 description 2
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 2
- 102100024152 Cadherin-17 Human genes 0.000 description 2
- 102100039536 Calcium-activated chloride channel regulator 1 Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 101710176668 Cartilage oligomeric matrix protein Proteins 0.000 description 2
- 102000004201 Ceramidases Human genes 0.000 description 2
- 108090000751 Ceramidases Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102100033423 GDNF family receptor alpha-1 Human genes 0.000 description 2
- 101000690766 Homo sapiens All-trans-retinol dehydrogenase [NAD(+)] ADH7 Proteins 0.000 description 2
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 2
- 101000762247 Homo sapiens Cadherin-17 Proteins 0.000 description 2
- 101000888572 Homo sapiens Calcium-activated chloride channel regulator 1 Proteins 0.000 description 2
- 101000997961 Homo sapiens GDNF family receptor alpha-1 Proteins 0.000 description 2
- 101001065832 Homo sapiens Low-density lipoprotein receptor class A domain-containing protein 4 Proteins 0.000 description 2
- 101000958771 Homo sapiens N-acylethanolamine-hydrolyzing acid amidase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100032094 Low-density lipoprotein receptor class A domain-containing protein 4 Human genes 0.000 description 2
- 102100038360 N-acylethanolamine-hydrolyzing acid amidase Human genes 0.000 description 2
- 101150060710 NPR1 gene Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 102100027881 Tumor protein 63 Human genes 0.000 description 2
- 101710140697 Tumor protein 63 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 102100038009 High affinity immunoglobulin epsilon receptor subunit beta Human genes 0.000 description 1
- 102100031672 Homeobox protein CDX-1 Human genes 0.000 description 1
- 102100030231 Homeobox protein cut-like 2 Human genes 0.000 description 1
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 description 1
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000878594 Homo sapiens High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 1
- 101000777808 Homo sapiens Homeobox protein CDX-1 Proteins 0.000 description 1
- 101000726714 Homo sapiens Homeobox protein cut-like 2 Proteins 0.000 description 1
- 101000977762 Homo sapiens Iroquois-class homeodomain protein IRX-5 Proteins 0.000 description 1
- 101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 1
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
- 101001056452 Homo sapiens Keratin, type II cytoskeletal 6A Proteins 0.000 description 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 1
- 101000739159 Homo sapiens Mammaglobin-A Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
- 101001057168 Homo sapiens Protein EVI2B Proteins 0.000 description 1
- 101100140242 Homo sapiens RDH11 gene Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000873502 Homo sapiens S-adenosylmethionine decarboxylase proenzyme Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101000642262 Homo sapiens Spondin-1 Proteins 0.000 description 1
- 101000946167 Homo sapiens Transcription factor LBX1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 102100023529 Iroquois-class homeodomain protein IRX-5 Human genes 0.000 description 1
- 102100038356 Kallikrein-2 Human genes 0.000 description 1
- 102100034866 Kallikrein-6 Human genes 0.000 description 1
- 102100025656 Keratin, type II cytoskeletal 6A Human genes 0.000 description 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 1
- 108010066789 Lymphocyte Antigen 96 Proteins 0.000 description 1
- 102000018671 Lymphocyte Antigen 96 Human genes 0.000 description 1
- 101150029107 MEIS1 gene Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100037273 Mammaglobin-A Human genes 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 101000690769 Mus musculus All-trans-retinol dehydrogenase [NAD(+)] ADH7 Proteins 0.000 description 1
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 description 1
- 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- 102100021873 NADPH oxidase 1 Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 description 1
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100027249 Protein EVI2B Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 102100023916 Retinol dehydrogenase 11 Human genes 0.000 description 1
- 102100035914 S-adenosylmethionine decarboxylase proenzyme Human genes 0.000 description 1
- 102000034543 SLC12 Human genes 0.000 description 1
- 108091006163 SLC12 Proteins 0.000 description 1
- 108091006620 SLC12A2 Proteins 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- 102000008145 Sodium-Potassium-Chloride Symporters Human genes 0.000 description 1
- 108010074941 Sodium-Potassium-Chloride Symporters Proteins 0.000 description 1
- 102100036428 Spondin-1 Human genes 0.000 description 1
- 108050000630 Transcription factor SOX-2 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011550 data transformation method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 108010069264 keratinocyte CD44 Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 208000005631 pseudoachondroplasia Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36866702P | 2002-03-29 | 2002-03-29 | |
| US60/368667 | 2002-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003203553A1 true AU2003203553A1 (en) | 2003-10-23 |
Family
ID=28675523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003203553A Abandoned AU2003203553A1 (en) | 2002-03-29 | 2003-03-28 | Cancer diagnostic panel |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7348142B2 (enExample) |
| EP (1) | EP1355150A3 (enExample) |
| JP (2) | JP4409845B2 (enExample) |
| KR (1) | KR20030078799A (enExample) |
| CN (2) | CN100577813C (enExample) |
| AR (1) | AR039210A1 (enExample) |
| AU (1) | AU2003203553A1 (enExample) |
| BR (1) | BR0303011A (enExample) |
| CA (1) | CA2422319A1 (enExample) |
| MX (1) | MXPA03002862A (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1151142A2 (en) * | 1999-01-28 | 2001-11-07 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
| US7348142B2 (en) * | 2002-03-29 | 2008-03-25 | Veridex, Lcc | Cancer diagnostic panel |
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| US10533998B2 (en) | 2008-07-18 | 2020-01-14 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| CA2475769C (en) * | 2003-08-28 | 2018-12-11 | Veridex, Llc | Colorectal cancer prognostics |
| US20050287544A1 (en) * | 2003-12-01 | 2005-12-29 | Francois Bertucci | Gene expression profiling of colon cancer with DNA arrays |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| WO2007017770A1 (en) * | 2005-08-05 | 2007-02-15 | Koninklijke Philips Electronics, N.V. | Search space coverage with dynamic gene distribution |
| JP2009508493A (ja) * | 2005-09-19 | 2009-03-05 | ベリデックス・エルエルシー | すい臓がんを診断するための方法 |
| US20070130694A1 (en) * | 2005-12-12 | 2007-06-14 | Michaels Emily W | Textile surface modification composition |
| EP3913375A1 (en) | 2006-01-11 | 2021-11-24 | Bio-Rad Laboratories, Inc. | Microfluidic devices and methods of use in the formation and control of nanoreactors |
| CN101437962A (zh) * | 2006-03-03 | 2009-05-20 | 维里德克斯有限责任公司 | 预测杜克氏b结肠癌复发的分子检测 |
| EP2021113A2 (en) | 2006-05-11 | 2009-02-11 | Raindance Technologies, Inc. | Microfluidic devices |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
| BRPI0720219A2 (pt) | 2006-12-08 | 2013-12-24 | Univ Iowa State Res Found Inc | Genes de planta envolvidos em absorção e metabolismo de nitrato |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| WO2010009365A1 (en) | 2008-07-18 | 2010-01-21 | Raindance Technologies, Inc. | Droplet libraries |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| US9512196B2 (en) | 2008-09-22 | 2016-12-06 | Cedars-Sinai Medical Center | Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling |
| EP2328911A4 (en) | 2008-09-22 | 2012-03-14 | Cedars Sinai Medical Center | SHORT HUMAN MD-2 AS A NEGATIVE REGULATOR OF GREAT LIKE RECEPTOR 4 SIGNALING |
| US9207242B2 (en) * | 2008-10-09 | 2015-12-08 | The University Of Hong Kong | Cadherin-17 as diagnostic marker and therapeutic target for liver cancer |
| WO2010111231A1 (en) | 2009-03-23 | 2010-09-30 | Raindance Technologies, Inc. | Manipulation of microfluidic droplets |
| US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
| WO2011042564A1 (en) | 2009-10-09 | 2011-04-14 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
| EP2517025B1 (en) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Methods for reducing the exchange of molecules between droplets |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| EP4484577A3 (en) | 2010-02-12 | 2025-03-26 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| EP3034628B1 (en) * | 2010-09-13 | 2018-10-24 | Clinical Genomics Pty Ltd | Diagnosis of cancer by means of methylation marker |
| EP2622103B2 (en) | 2010-09-30 | 2022-11-16 | Bio-Rad Laboratories, Inc. | Sandwich assays in droplets |
| WO2012109600A2 (en) | 2011-02-11 | 2012-08-16 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
| US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| WO2013120089A1 (en) | 2012-02-10 | 2013-08-15 | Raindance Technologies, Inc. | Molecular diagnostic screening assay |
| WO2013165748A1 (en) | 2012-04-30 | 2013-11-07 | Raindance Technologies, Inc | Digital analyte analysis |
| EP2986762B1 (en) | 2013-04-19 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| WO2014205266A2 (en) * | 2013-06-20 | 2014-12-24 | The Broad Institute | Compositions and methods for detecting and treating glioblastoma |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| CN106086220A (zh) * | 2016-08-19 | 2016-11-09 | 浙江省中医院 | 一种非小细胞肺癌单核苷酸多态性检测试剂盒及其应用 |
| US10998178B2 (en) | 2017-08-28 | 2021-05-04 | Purdue Research Foundation | Systems and methods for sample analysis using swabs |
| WO2019144275A1 (zh) * | 2018-01-23 | 2019-08-01 | 北京艾克伦医疗科技有限公司 | 鉴定肺癌状态的方法和试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US6350576B1 (en) | 1994-12-20 | 2002-02-26 | Cold Spring Harbor Laboratory | Cancer detection probes |
| US5695937A (en) * | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US6275814B1 (en) | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| MXPA01009369A (es) | 1999-03-15 | 2003-06-06 | Eos Biotechnology Inc | Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal. |
| US6175824B1 (en) | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
| RU2251838C2 (ru) | 1999-07-15 | 2005-05-20 | Рисерч Дивелопмент Фаундейшн | Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование |
| US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
| US7105293B2 (en) * | 2000-09-19 | 2006-09-12 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
| CA2439074A1 (en) * | 2001-03-09 | 2002-09-19 | Nugen Technologies, Inc. | Methods and compositions for amplification of rna sequences |
| US20030138793A1 (en) * | 2001-06-10 | 2003-07-24 | Irm Llc, A Delaware Limited Liability Company | Molecular signatures of commonly fatal carcinomas |
| US7348142B2 (en) * | 2002-03-29 | 2008-03-25 | Veridex, Lcc | Cancer diagnostic panel |
-
2003
- 2003-03-21 US US10/393,567 patent/US7348142B2/en not_active Expired - Fee Related
- 2003-03-28 BR BR0303011-3A patent/BR0303011A/pt not_active Application Discontinuation
- 2003-03-28 AU AU2003203553A patent/AU2003203553A1/en not_active Abandoned
- 2003-03-28 CA CA002422319A patent/CA2422319A1/en not_active Abandoned
- 2003-03-29 CN CN03131207A patent/CN100577813C/zh not_active Expired - Fee Related
- 2003-03-29 KR KR10-2003-0019811A patent/KR20030078799A/ko not_active Withdrawn
- 2003-03-29 CN CN200910224989A patent/CN101705291A/zh active Pending
- 2003-03-31 MX MXPA03002862A patent/MXPA03002862A/es active IP Right Grant
- 2003-03-31 EP EP03252023A patent/EP1355150A3/en not_active Withdrawn
- 2003-03-31 JP JP2003096170A patent/JP4409845B2/ja not_active Expired - Fee Related
- 2003-04-01 AR ARP030101131A patent/AR039210A1/es not_active Application Discontinuation
-
2008
- 2008-01-29 US US12/021,439 patent/US20090221445A1/en not_active Abandoned
-
2009
- 2009-03-03 JP JP2009049600A patent/JP2009118855A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US7348142B2 (en) | 2008-03-25 |
| JP2009118855A (ja) | 2009-06-04 |
| AR039210A1 (es) | 2005-02-09 |
| JP2004033215A (ja) | 2004-02-05 |
| CN100577813C (zh) | 2010-01-06 |
| CN101705291A (zh) | 2010-05-12 |
| MXPA03002862A (es) | 2004-08-11 |
| EP1355150A3 (en) | 2004-08-25 |
| CN1495275A (zh) | 2004-05-12 |
| CA2422319A1 (en) | 2003-09-29 |
| EP1355150A2 (en) | 2003-10-22 |
| KR20030078799A (ko) | 2003-10-08 |
| JP4409845B2 (ja) | 2010-02-03 |
| BR0303011A (pt) | 2004-02-17 |
| US20090221445A1 (en) | 2009-09-03 |
| US20030194733A1 (en) | 2003-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100577813C (zh) | 肿瘤诊断组合物 | |
| US20030194734A1 (en) | Selection of markers | |
| AU2003203557B2 (en) | Breast cancer prognostic portfolio | |
| US20040146907A1 (en) | Methods and compositions for detecting dysplasia | |
| US9587279B2 (en) | Thyroid tumors identified | |
| CA2430981A1 (en) | Gene expression profiling of primary breast carcinomas using arrays of candidate genes | |
| US20040241725A1 (en) | Lung cancer detection | |
| BRPI0708534A2 (pt) | ensaio molecular para prognosticar a recorrência de cáncer do cólon dukes b | |
| AU2006203169A1 (en) | Predicting bone relapse of breast cancer | |
| BRPI0616090A2 (pt) | métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida | |
| CA2403946A1 (en) | Genes expressed in foam cell differentiation | |
| AU2008203227A1 (en) | Colorectal cancer prognostics | |
| KR102422776B1 (ko) | 생검 분석용 유전자 패널 및 이를 이용한 개인 맞춤형 치료 방법 | |
| US20030013099A1 (en) | Genes regulated by DNA methylation in colon tumors | |
| CA3067730A1 (en) | Methods for detection of plasma cell dyscrasia | |
| KR20070090110A (ko) | 위 암종으로부터의 림프절 전이의 검출법 | |
| AU2004205270B2 (en) | Colorectal cancer prognostics | |
| WO2007135174A1 (de) | Praediktives genexpressionsmuster fuer kolorektale karzinome | |
| HK1141054A (en) | Tumor diagnostic composition | |
| CN1890385A (zh) | 结肠直肠癌相关基因 | |
| CA3064732A1 (en) | Methods for melanoma detection | |
| CN101405406A (zh) | 诊断胰癌的方法 | |
| MXPA04008401A (en) | Colorectal cancer prognostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |